An interventional study of CanRisk and Standard clinical risk assessment in Ovarian Cancer, sponsored by Instituto Portugues Oncologia de Lisboa Francisco Gentil. Recruiting at 6 sites in 4 countries. Open to female participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Instituto Portugues Oncologia de Lisboa Francisco Gentil · Not applicable, Interventional, and Other
Among 62 studies in Ovarian Neoplasms with a site in Czechia — 13 open to participants now, 23 under way, 12 of them phase 3. Ovarian Neoplasms · Czechia.
Among the 62 studies in Ovarian Neoplasms with a site in Czechia, this one has the largest planned enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2026, is one of 6 with no phase, reaches primary completion later than 14 of the 22 other live ones, and was the 62nd registered.
3,381 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.
Browse Ovarian Neoplasms studies →13 of the 62 studies in Ovarian Neoplasms with a site in Czechia are open now. Recruiting first, the newest first:
National and Kapodistrian University of Athens · Sites in Czechia, Greece, Lithuania and 2 more countries
Merck Sharp & Dohme LLC · Sites in Czechia, United States, Argentina and 27 more countries
AbbVie · Sites in Czechia, United States, Australia and 5 more countries
Eli Lilly and Company · Sites in Czechia, United States, Australia and 24 more countries
KU Leuven · Sites in Czechia, Belgium, Italy
A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →
Of the 606 Ovarian Neoplasms studies recruiting now, 443 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years to 75 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 15 · Phase 3 31 · Phase 4 1
First in 1998; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 2,130 is above the median of 54 across 2,548 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 406 across the 53 interventional studies, 300 across the 8 observational. Of the 37 that completed or were terminated, 18 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 62 have an industry lead sponsor. The 10 most frequent:
Instituto Portugues Oncologia de Lisboa Francisco Gentil is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Instituto Portugues Oncologia de Lisboa Francisco Gentil has 1 study filed under Ovarian Neoplasms — fewer than ten, so there is no comparison to draw.
7 of the studies in Ovarian Neoplasms with a site in Czechia that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT04498117Phase 3CanariaBio Inc.Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | 2026-12-26 |
| NCT05445778Phase 3AbbVieMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | 2027-04 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT06689605University Hospital Hradec KraloveUltrasound-guided Tru-cut Biopsy in Patients with Suspected Ovarian Cancer: Adequacy, Accuracy, Safety and Patient Assessment. | 2026-12 |
Among the 62 studies in Ovarian Neoplasms with a site in Czechia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to improve how the risk of developing ovarian cancer is assessed in people who may be at increased risk of ovarian cancer due to their family history or genetic background.
In current clinical practice, ovarian cancer risk assessment usually relies on information about cancer in the family and, in some cases, genetic testing for certain genes known to be associated with ovarian cancer. While this approach is commonly used, the inclusion of additional factors may support more personalised ovarian cancer risk assessment.
This study compares two approaches to ovarian cancer risk assessment:
By comparing these two approaches, the study aims to understand whether the personalised risk assessment tool, CanRisk, can be used in everyday clinical care. To do this, researchers will investigate whether the CanRisk tool is feasible in clinical practice, acceptable to both healthcare professionals and persons receiving a risk assessment, as well as whether it can be delivered in a cost-effective way.
The study does not involve people who have been diagnosed with ovarian cancer. It focuses on individuals who are currently cancer-free and are undergoing assessment because they may have an increased risk of ovarian cancer.
Ovarian cancer (OC) is one of the leading causes of gynaecological cancer mortality in Europe, largely due to late diagnosis and the absence of effective population-level screening. Identifying women at increased risk is therefore essential to enable targeted prevention and early detection strategies. The CanRisk tool is a CE-marked multifactorial risk prediction tool that integrates family history, genetic and non-genetic factors to provide personalised risk estimates. While the tool has been validated extensively and is endorsed by international and European guidelines, the collection of data on its real-world feasibility, acceptability, and cost-effectiveness could enhance adoption in routine clinical practice. The CSA study contributes to this goal by comparing CanRisk-based risk assessment with standard practice across clinical sites in four European countries, generating key evidence for future implementation of precision prevention approaches in OC. The DISARM Clinical Study A (CSA) is a multisite, multi-country, non-commercial, low interventional randomised controlled study designed to evaluate the implementation of multifactorial ovarian cancer risk assessment using the CanRisk tool compared with standard practice. The study aims to assess the feasibility, acceptability and cost-effectiveness of CanRisk-based ovarian cancer risk assessment across clinical sites in Greece, Portugal, the Czech Republic and Lithuania.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive ovarian cancer risk assessment using the CanRisk tool incorporating personal and family history, genetic testing results, and a polygenic risk score (PRS), in addition to standard clinical management.
Other: CanRisk
Participants receive standard clinical genetic assessment and management according to national clinical practice without CanRisk-guided risk estimation
Other: Standard clinical risk assessment
Risk assessment using the CanRisk tool, incorporating personal and family history, genetic testing results and polygenic risk score (PRS), to provide individualized ovarian cancer risk estimation.
Standard clinical genetic counselling, genetic testing and risk assessment according to national clinical practice, without use of the CanRisk tool.
Recruitment Rate
Proportion of eligible individuals who consent to enroll in the study.
Time frame: Month 12
Retention Rate
Proportion of enrolled participants who complete the study through final assessment.
Time frame: Month 12
CanRisk Data Completeness
Proportion of CanRisk assessments completed with full data entry.
Time frame: Month 12
Time to Complete CanRisk Assessment vs. Standard Practice
Average time required to complete a CanRisk-based risk assessment compared with standard practice risk assessment.
Time frame: Month 12
Consultation and Assessment Workflow Timelines
Time required for consultation and assessment workflow processes associated with the CanRisk-based assessment.
Time frame: Month 12
Usability of CanRisk (System Usability Scale)
Usability of the CanRisk tool as rated by healthcare professionals using the System Usability Scale (SUS), assessed at mid-study and end of study.
Time frame: Month 6 & 12
Qualitative Implementation Assessment (CFIR)
Number and type of implementation barriers and facilitators identified through qualitative assessment guided by the Consolidated Framework for Implementation Research (CFIR), at end of study.
Time frame: Month 12
Acceptability by Healthcare Professionals (TFA Questionnaire)
Acceptability of CanRisk-based assessment among healthcare professionals, measured using the Theoretical Framework of Acceptability (TFA) Generic Questionnaire, assessed at mid-study and end of study.
Time frame: Month 6 &12
HCP Satisfaction with CanRisk vs. Standard Practice
Proportion of healthcare professionals reporting satisfaction with CanRisk versus standard practice assessment, assessed at mid-study and end of study.
Time frame: Month 6 & 12
HCP Willingness to Continue Using CanRisk
Proportion of healthcare professionals indicating willingness to continue using CanRisk after study completion, assessed at mid-study and end of study.
Time frame: Month 6 & 12
Qualitative Feedback from Healthcare Professionals
Number and type of themes identified from focus groups and/or semi-structured interviews with healthcare professionals, at end of study.
Time frame: Month 12
Acceptability by Study Participants (TFA Questionnaire)
Acceptability of risk assessment results among study participants, measured using the TFA Generic Questionnaire, administered immediately after delivery of results.
Time frame: Immediately following delivery of risk assessment results
Incremental Mean Cost per Participant
Incremental mean cost per participant at 12 months, including assessment-related and downstream care costs incurred within follow-up.
Time frame: Month 12
Incremental Cost per Completed Risk Assessment
Incremental cost per completed CanRisk-based risk assessment.
Time frame: Month 12
Incremental Quality-Adjusted Life Years (QALYs)
Incremental quality-adjusted life years accrued over 12 months, comparing CanRisk-based assessment to standard practice.
Time frame: Month 12
Descriptive Subgroup Summaries of Costs and Outcomes
Descriptive summary of costs and outcomes across pre-specified subgroups.
Time frame: Month 12
Started Aug 2026 (actual). Primary completion is estimated for Sep 2028, 25 months after the start.
Of 282 non-industry interventional studies with no phase under Ovarian Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 76. This study's planned 25 months is below that.
Counting every sponsor, half of 293 studies reached it within 46 months; a quarter within 23 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto Portugues Oncologia de Lisboa Francisco Gentil